Page last updated: 2024-12-05

sultopride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Sultopride is a typical antipsychotic medication primarily used to treat schizophrenia and other psychotic disorders. Its chemical structure is a benzamide derivative with a sulfo group. Sultopride works by blocking dopamine receptors in the brain, particularly D2 receptors. This action helps to alleviate psychotic symptoms such as hallucinations and delusions. While sultopride is considered a typical antipsychotic, it has a relatively high affinity for D2 receptors and a lower affinity for D3 receptors compared to other typical antipsychotics, which may contribute to its lower risk of extrapyramidal symptoms (EPS) like tremor and muscle rigidity. Sultopride is typically administered orally, and its effects are generally observed within a few weeks. Its clinical importance lies in its efficacy in managing positive symptoms of psychosis while potentially having a lower risk of EPS compared to other antipsychotics. Studies on sultopride focus on its efficacy, safety, and pharmacokinetic properties in treating psychotic disorders, as well as its potential applications in other conditions such as Tourette's syndrome. Research also aims to understand its mechanism of action and optimize its therapeutic use.'

Cross-References

ID SourceID
PubMed CID5357
CHEMBL ID277945
CHEBI ID9356
SCHEMBL ID149197
MeSH IDM0058775

Synonyms (53)

Synonym
brn 0494772
sultroprida [inn-spanish]
o-anisamide, n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-
einecs 258-641-9
benzamide, n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-
sultopride [inn:dcf]
n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-o-anisamide
sultopridum [inn-latin]
topral
lin 1418
lin-1418
barnetil
n-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-(methyloxy)benzamide
PDSP1_001575
PDSP2_001559
sultopride
53583-79-2
chebi:9356 ,
CHEMBL277945
L001065
sultopride (inn)
D08549
n-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
bdbm86720
cas_53583-79-2
nsc_5357
5-22-08-00103 (beilstein handbook reference)
unii-aa0g3tw31w
aa0g3tw31w ,
sultroprida
sultopridum
942650-31-9
sultopride [who-dd]
sultopride [inn]
(+/-)-sultopride
sultopride [mi]
n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
(+/-)-n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
SCHEMBL149197
KS-5337
AKOS024255726
UNRHXEPDKXPRTM-UHFFFAOYSA-N
n-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide
DTXSID9023627
rac-ethylenebis(1-indenyl)dimethylzirconium(iv)
FT-0725190
HY-42849
CS-0040602
Q4445779
n-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
DB13273
EN300-18563734
5-(ethanesulfonyl)-n-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
salicylamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID117621Motility against number of interrupted beams in 1 hour in naive mice by 10 determinations1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID50163Compound was evaluated for the inhibition of carbonic anhydrase enzyme at 1.0 g/L concentration; a=No inhibition detected1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis and inhibitory activity on carbonic anhydrase of some new sulpiride analogues studied by means of a new method.
AID117630Motility against number of interrupted beams in 1 hr in reserpine & apomorphine treated mice by 11 determinations1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID50165Compound was evaluated for the inhibition of carbonic anhydrase enzyme at 1.5 g/L concentration; a=No inhibition detected1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis and inhibitory activity on carbonic anhydrase of some new sulpiride analogues studied by means of a new method.
AID50159Compound was evaluated for the inhibition of carbonic anhydrase enzyme at 0.2 g/L concentration; a=No inhibition detected1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis and inhibitory activity on carbonic anhydrase of some new sulpiride analogues studied by means of a new method.
AID180436Compound was evaluated for the homovanillic acid levels of rats limbic system by 6 determinations1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID50167Compound was evaluated for the inhibition of carbonic anhydrase enzyme at 2.0 g/L concentration; a=No inhibition detected1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis and inhibitory activity on carbonic anhydrase of some new sulpiride analogues studied by means of a new method.
AID176655Subcutaneous dose to inhibit apomorphine-induced stereotyped behavior in 50% of rats1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds.
AID50161Compound was evaluated for the inhibition of carbonic anhydrase enzyme at 0.5 g/L concentration; a=No inhibition detected1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Synthesis and inhibitory activity on carbonic anhydrase of some new sulpiride analogues studied by means of a new method.
AID180429Compound was evaluated for the homovanillic acid levels of rats Corpus striata by 7 determinations1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.77 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]